Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer
Background Pembrolizumab has become standard neoadjuvant systemic therapy (NST) for early estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-normal early breast cancer (eBC). Electronic health record (EHR) data may support real-world assessment of its implementation in routine care. Patien...